Clinical Trial Update: An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer [Phase 2]

View source ↗

Summary

Open-label Phase II trial of AZD4635 in prostate cancer, including metastatic castration-resistant disease; trial completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• AZD4635 (AZD4635)

Snippet

Sponsor: AstraZeneca | Conditions: Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Status: COMPLETED | Results posted: 2022-07-08